Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Abstract excerpt

First line standard therapeutic approaches in elderly high-risk (HR) MDS or AML patients are largely based on hypomethylating agents (HMAs) including azacitidine (AZA) or decitabine (DAC), but responses are generally short-lived and occur only in 50–60% of patients [ 1 , 2 ]. Patients failing HMAs have a dismal prognosis with a median survival of around 5 months [ 3 ]. The high unmet medical need for new...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Histone Deacetylase Inhibitors Research
• Share to Immune Cell Function and Interaction